Potential of Sorbus berry extracts for management of type 2 diabetes: metabolomics investigation of 1H NMR spectra, α-amylase and α-glucosidase inhibitory activities, and in vivo anti-hyperglycaemic activity of S. norvegica
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Potential of Sorbus berry extracts for management of type 2 diabetes: metabolomics investigation of 1H NMR spectra, α-amylase and α-glucosidase inhibitory activities, and in vivo anti-hyperglycaemic activity of S. norvegica. / Broholm, Sofie L.; Gramsbergen, Simone; Nyberg, Nils; Jäger, Anna K; Stærk, Dan.
In: Journal of Ethnopharmacology, Vol. 242, 112061, 2019.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Potential of Sorbus berry extracts for management of type 2 diabetes: metabolomics investigation of 1H NMR spectra, α-amylase and α-glucosidase inhibitory activities, and in vivo anti-hyperglycaemic activity of S. norvegica
AU - Broholm, Sofie L.
AU - Gramsbergen, Simone
AU - Nyberg, Nils
AU - Jäger, Anna K
AU - Stærk, Dan
PY - 2019
Y1 - 2019
N2 - Ethnopharmacological relevance: Berries of Sorbus species have been used to treat type 2 diabetes in many regions in Europe.Aims of the study: To investigate the inhibitory activity of berry extract of Sorbus on the digestive enzymes α-amylase and α-glucosidase, two important targets for management of blood glucose for type 2 diabetics. Furthermore, to test the anti-hyperglycaemic potential of S. norvegica berry extract in vivo.Materials and Methods: 70 % acetone berry extracts of 16 Sorbus species were tested in vitro for inhibition of α-amylase and α-glucosidase. Single berry extracts were analysed by 1H-NMR spectroscopy and principal component analysis to evaluate the chemical profiles of the extracts. The anti-hyperglycaemic effect was evaluated in an oral starch tolerance test in STZ-treated C57BL/6 mice.Results: The lowest IC50 values against α-amylase and α-glucosidase were obtained with the Sorbus species belonging to the subspecies Aria, which have simple leaves compared to pinnately compound leaves of the other Sorbus species. Species belonging to subspecies Aria grouped together and away from the other Sorbus species in the score plot, indicating a difference in chemistry. Both the carbohydrate- and polyphenol-fraction contributed to the enzyme inhibition. Extract of the most active species, S. norvegica, had anti-hyperglycaemic activity, at a level 36 times lower than clinically used acarbose, corresponding to a needed daily dose of 900 mg extract. Conclusions: Sorbus species of subspecies Aria have the potential to be used for management of type 2 diabetes.
AB - Ethnopharmacological relevance: Berries of Sorbus species have been used to treat type 2 diabetes in many regions in Europe.Aims of the study: To investigate the inhibitory activity of berry extract of Sorbus on the digestive enzymes α-amylase and α-glucosidase, two important targets for management of blood glucose for type 2 diabetics. Furthermore, to test the anti-hyperglycaemic potential of S. norvegica berry extract in vivo.Materials and Methods: 70 % acetone berry extracts of 16 Sorbus species were tested in vitro for inhibition of α-amylase and α-glucosidase. Single berry extracts were analysed by 1H-NMR spectroscopy and principal component analysis to evaluate the chemical profiles of the extracts. The anti-hyperglycaemic effect was evaluated in an oral starch tolerance test in STZ-treated C57BL/6 mice.Results: The lowest IC50 values against α-amylase and α-glucosidase were obtained with the Sorbus species belonging to the subspecies Aria, which have simple leaves compared to pinnately compound leaves of the other Sorbus species. Species belonging to subspecies Aria grouped together and away from the other Sorbus species in the score plot, indicating a difference in chemistry. Both the carbohydrate- and polyphenol-fraction contributed to the enzyme inhibition. Extract of the most active species, S. norvegica, had anti-hyperglycaemic activity, at a level 36 times lower than clinically used acarbose, corresponding to a needed daily dose of 900 mg extract. Conclusions: Sorbus species of subspecies Aria have the potential to be used for management of type 2 diabetes.
U2 - 10.1016/j.jep.2019.112061
DO - 10.1016/j.jep.2019.112061
M3 - Journal article
C2 - 31283956
VL - 242
JO - Journal of Ethnopharmacology
JF - Journal of Ethnopharmacology
SN - 0378-8741
M1 - 112061
ER -
ID: 218696717